Harrow, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Harrow, Inc. (HROW) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $0 as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-10
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $0.00.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $11.77M.
- 2025-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $18.05M.
- 2024-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $5.17M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 |
| 2025-06-30 | $11.77M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $18.05M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $5.17M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $10.67M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $15.90M 10-Q · filed 2024-05-13 |
| 2023-09-30 | $5.35M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $9.81M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $14.14M 10-Q · filed 2023-05-11 |
| 2022-09-30 | $1.62M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.23M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $4.85M 10-Q · filed 2022-05-05 |
| 2021-09-30 | $2.77M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $3.31M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $3.40M 10-Q · filed 2021-05-11 |
| 2020-09-30 | $1.30M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $2.44M 10-Q · filed 2020-08-10 |
| 2018-03-31 | $1.71M 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |